Report Overview

The Antifungal drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Antifungal drugs are used to treat fungal infections caused by a wide range of fungi. Common fungal infections prevalent among Kenyan population are Tinea capitis, Oral candidiasis, Oesophageal candidiasis, Vaginal candidiasis, Chronic Pulmonary Aspergillosis, Cryptococcal meningitis, Pneumocystis pneumonia and Fungal keratitis. The high burden of fungal infections may be attributed to opportunistic infections in HIV and TB patients. It is estimated that, at any one time, about 7% of the Kenyan population suffers from a significant fungal infection, with recurrent vaginitis and tinea capitis accounting for 82% of the infections.The antifungal drugs are available in different formulations (oral tablet, oral capsule, cream, shampoo, sterile IV solution, lotion, vaginal cream, and ointments).



Market Drivers

The market is majorly driven due to the high prevalence of fungal infections in Kenya.

Approximately 594,660 Kenyan women get more than 4 episodes Candida vulvovaginitis annually and Tinea capitis infects 9.6% of children in Kenya.

Oral thrush, Oesophageal candidiasis, Cryptococcal meningitis and Pneumocystis pneumonia are common opportunistic infection among HIV infected patients.Chronic Pulmonary Aspergillosis is prevalent following Tuberculosis infection.

Kenya has approximately 40% of its population in the age group 0-15 years. This age group is highly susceptible to fungal infections like Tinea capitis.

Increase in the number of hospital-acquired infections is expected to augment growth of antifungal drug market.

In most parts of the coast, relative humidity is high year-round which presents ideal temperature of the fungi to thrive and grow causing high incidence of fungal infections in coastal regions.

However, increased resistance has been observed among the Candida and Aspergillus species towards antifungal drugs is restraining the growth of antifungal market.